外用10%特比萘芬溶液(MOB-015)治疗轻中度远端甲下甲真菌病的3期研究
这项多中心、双盲、赋形剂对照的3期研究纳入轻中度远端及侧位甲下甲真菌病患者,随机接受MOB-015或赋形剂每日一次治疗48周。第52周时MOB-015组真菌学治愈率为69.9%,赋形剂组为27.7%(P < .001);完全治愈率分别为4.5%和0%(P = .0195)。MOB-015的不良事件特征与赋形剂相似,可作为甲真菌病的治疗选择。
要点
- MOB-015每日一次治疗48周,第52周真菌学治愈率69.9%显著高于赋形剂27.7%。
- 完全治愈率MOB-015组4.5%,赋形剂组0%,差异有统计学意义(P = .0195)。
- 因不良事件停药比例MOB-015组2.8%,赋形剂组4.2%,安全性相似。
核心结论
- MOB-015是甲真菌病的治疗选择,其不良事件特征与赋形剂相似。
研究设计与样本
- 多中心、双盲、赋形剂对照的3期北美研究,纳入轻中度远端及侧位甲下甲真菌病患者,受累至少1个大脚趾甲的20%至60%,随机每日一次应用MOB-015或匹配赋形剂治疗48周。
主要发现
- 第52周真菌学治愈(培养阴性且氢氧化钾显微镜检查阴性)率MOB-015组为69.9%,赋形剂组为27.7%(P < .001)。
- 第52周完全治愈(临床疾病受累0%且真菌学治愈)率MOB-015组为4.5%,赋形剂组为0%(P = .0195)。
- 导致停药的不良事件发生率MOB-015组为2.8%,赋形剂组为4.2%。
关键数值与推荐
- 主要疗效指标为完全治愈,次要疗效指标为真菌学治愈和治疗成功。
- 真菌学治愈定义为培养阴性且氢氧化钾显微镜检查阴性。
- 完全治愈定义为临床疾病受累0%且真菌学治愈。
临床怎么用
- 对于轻中度远端及侧位甲下甲真菌病,可考虑每日一次外用MOB-015治疗48周。
- 治疗期间需关注不良事件,因不良事件停药比例较低。
局限性
- 治疗结束后的随访期可能不足以准确反映远端及侧位甲下甲真菌病的治愈情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Onychomycosis is a recalcitrant fungal nail infection. Topical antifungal agents may be preferred over systemic agents due to lack of systemic adverse effects. OBJECTIVE: To investigate the efficacy and safety of topical terbinafine 10% solution (MOB-015) for the treatment of distal and lateral subungual onychomycosis. METHODS: In a multicenter, double-blind, phase III, North American study, patients with mild to moderate distal and lateral subungual onychomycosis involving 20% to 60% of at least 1 great toenail were randomized to once daily application of MOB-015 or matching vehicle for 48 weeks. The primary efficacy variable was complete cure, while the secondary efficacy variables were mycological cure and treatment success. Safety evaluations were also performed. RESULTS: At week 52, the mycological cure (negative culture and potassium hydroxide microscopy) rate in the MOB-015 and vehicle groups was 69.9% and 27.7%, respectively (P < .001), and complete cure (0% clinical disease involvement and mycological cure) was achieved in 4.5% and 0% of patients, respectively (P = .0195). At least 1 adverse event leading to discontinuation of treatment occurred in 2.8% of patients in the MOB-015 group and in 4.2% in the vehicle group. LIMITATION: The follow-up period after end of treatment may not be sufficient to accurately reflect cure in distal and lateral subungual onychomycosis. CONCLUSIONS: MOB-015 is a treatment option for onychomycosis with an adverse event profile similar to vehicle.
引用
- Gupta AK, Surprenant MS, Kempers SE, et al. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study. J Am Acad Dermatol. 2020. PMID: 32585278. doi:10.1016/j.jaad.2020.06.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。